Literature DB >> 23614760

The gender-paradox among patients with implantable cardioverter-defibrillators: a propensity-matched study.

Sanjeev P Bhavnani1, Vamsimohan Pavuluri, Craig I Coleman, Danette Guertin, Ravi K Yarlagadda, Christopher A Clyne, Jeffery Kluger.   

Abstract

BACKGROUND: Several meta-analyses of the implantable cardioverter-defibrillator (ICD) clinical trials have demonstrated that while men derived a mortality reduction with prophylactic ICD implantation, women did not. These trials also observed that women receive less appropriate ICD shock therapy compared to men. We aimed to investigate this "gender-paradox" among a heterogeneous community cohort of patients receiving ICDs.
METHODS: We identified 1,445 consecutive patients undergoing ICD implantation from 1997 to 2007. The study population consisted of 582 patients, of whom 291 were women who could be propensity matched to 291 men, based on age, ejection fraction, implantation indication (primary or secondary), etiology of cardiomyopathy (ischemic or nonischemic), and the presence of a cardiac resynchronization therapy-defibrillator (CRT-D) device. The impact of gender difference on the probability of death and appropriate ICD shocks for ventricular arrhythmias was calculated using multivariable Cox proportional hazards analyses.
RESULTS: During a mean follow-up of 909 ± 901 days, compared to men, women demonstrated a similar risk of death (25% vs 25%, adjusted hazard ratio [AHR] 1.05 [95% confidence interval (CI) 0.81-1.35], P = 0.74). In contrast, women demonstrated a decreased probability of appropriate ICD-shock therapy (14% vs 19%, AHR 0.80 [95% CI 0.59-0.88], P = 0.03) compared to men, and among cohorts with a nonischemic cardiomyopathy (10% vs 20%, P < 0.001) and CRT-D devices (7% vs 19%, P = 0.01).
CONCLUSION: Among a community cohort with ICDs, women have a similar mortality compared to men while experiencing less appropriate ICD therapy. These results support the findings of a lower arrhythmic mortality among women. ©2013, The Authors. Journal compilation ©2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  gender; implantable cardioverter-defibrillator; mortality; risk stratification; shocks

Mesh:

Year:  2013        PMID: 23614760     DOI: 10.1111/pace.12141

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  10 in total

1.  Advances in Cardiovascular Health in Women over the Past Decade: Guideline Recommendations for Practice.

Authors:  Pejman Raeisi-Giglou; Annabelle Santos Volgman; Hena Patel; Susan Campbell; Amparo Villablanca; Eileen Hsich
Journal:  J Womens Health (Larchmt)       Date:  2017-07-17       Impact factor: 2.681

2.  Gender and outcomes after primary prevention implantable cardioverter-defibrillator implantation: Findings from the National Cardiovascular Data Registry (NCDR).

Authors:  Andrea M Russo; Stacie L Daugherty; Frederick A Masoudi; Yongfei Wang; Jeptha Curtis; Rachel Lampert
Journal:  Am Heart J       Date:  2015-04-23       Impact factor: 4.749

Review 3.  ICD and CRT use in ischemic heart disease in women.

Authors:  Nishaki Kiran Mehta; William T Abraham; Melanie Maytin
Journal:  Curr Atheroscler Rep       Date:  2015-06       Impact factor: 5.113

Review 4.  Impact of sex and ethnicity on arrhythmic risk.

Authors:  Santosh Rane; Kristen K Patton
Journal:  Curr Cardiol Rep       Date:  2015-07       Impact factor: 2.931

5.  Primary prevention implantable cardioverter-defibrillators and survival in older women.

Authors:  Emily P Zeitler; Anne S Hellkamp; Gregg C Fonarow; Stephen C Hammill; Lesley H Curtis; Adrian F Hernandez; Hussein R Al-Khalidi; Jeptha P Curtis; Paul A Heidenreich; Kevin J Anstrom; Eric D Peterson; Daniel B Mark; Bradley G Hammill; Gillian D Sanders; Sana M Al-Khatib
Journal:  JACC Heart Fail       Date:  2014-11-05       Impact factor: 12.035

6.  Analysis of ECG Measures of Cardiac Repolarization in Relation to Arrhythmic Events in an Implantable Cardioverter Defibrillator Population.

Authors:  Bijia Shi; Scott Harding; Peter Larsen
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-06-13       Impact factor: 1.468

7.  Sex Differences in Utilisation and Response to Implantable Device Therapy.

Authors:  Deepika Narasimha; Anne B Curtis
Journal:  Arrhythm Electrophysiol Rev       Date:  2015-08

8.  Age and sex differences in long-term outcomes following implantable cardioverter-defibrillator placement in contemporary clinical practice: findings from the Cardiovascular Research Network.

Authors:  Frederick A Masoudi; Alan S Go; David J Magid; Andrea E Cassidy-Bushrow; Jerry H Gurwitz; Taylor I Liu; Kristi Reynolds; David H Smith; Liza M Reifler; Karen A Glenn; Frances Fiocchi; Robert Goldberg; Nigel Gupta; Pamela N Peterson; Claudio Schuger; Humberto Vidaillet; Stephen C Hammill; Robert T Greenlee
Journal:  J Am Heart Assoc       Date:  2015-06-02       Impact factor: 5.501

9.  Primary Prevention Implantable Cardioverter Defibrillator (ICD) Therapy in Women-Data From a Multicenter French Registry.

Authors:  Rui Providência; Eloi Marijon; Pier D Lambiase; Abdeslam Bouzeman; Pascal Defaye; Didier Klug; Denis Amet; Marie-Cécile Perier; Daniel Gras; Vincent Algalarrondo; Jean-Claude Deharo; Christophe Leclercq; Laurent Fauchier; Dominique Babuty; Pierre Bordachar; Nicolas Sadoul; Olivier Piot; Serge Boveda
Journal:  J Am Heart Assoc       Date:  2016-02-12       Impact factor: 5.501

10.  Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter-Defibrillators in the Cardiovascular Research Network.

Authors:  Robert T Greenlee; Alan S Go; Pamela N Peterson; Andrea E Cassidy-Bushrow; Charles Gaber; Romel Garcia-Montilla; Karen A Glenn; Nigel Gupta; Jerry H Gurwitz; Stephen C Hammill; John J Hayes; Alan Kadish; David J Magid; David D McManus; Deborah Multerer; J David Powers; Liza M Reifler; Kristi Reynolds; Claudio Schuger; Param P Sharma; David H Smith; Mary Suits; Sue Hee Sung; Paul D Varosy; Humberto J Vidaillet; Frederick A Masoudi
Journal:  J Am Heart Assoc       Date:  2018-03-26       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.